shuchita kaila - HEOR Value Demonstrat Team, Boehringer Ingelheim Pharmaceut Inc

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 46 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

P-170 Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing among Patients with Multiple Myeloma

Lucio Gordan, Amanda Warner,Trevor Heritage, Amy Ming,Niodita Gupta-Werner,Shuchita Kaila,Annelore Cortoos

Clinical Lymphoma Myeloma & Leukemia (2024): S234-S234

引用0浏览0引用

Clinical Consensus on Treatments for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Double-Blinded Delphi Panel

Rafael Fonseca,Adriana Rossi,Rohan Medhekar,Jennifer Voelker, Trevor Homan, Jessica Wilcock,Anna Karakusevic,James Cochrane,Daisy Bridge, Richard Perry,Shuchita Kaila,Faith E. Davies

FUTURE ONCOLOGY (2024)

引用0浏览0WOS引用

Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (drd) and Bortezomib, Lenalidomide, and Dexamethasone (vrd) in Transplant Ineligible Patients with Multiple Myeloma

Doris K. Hansen,Santosh Gautam,Marie-Helene Lafeuille,Carmine Rossi,Bronwyn Moore,Anabelle Tardif-Samson,Philippe Thompson-Leduc,Alex Z. Fu,Annelore Cortoos,Shuchita Kaila,Rafael Fonseca

Cancer Medicineno. 21 (2024): n/a-n/a

引用0浏览0WOS引用

P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US

Adam F. Binder,Urvi A. Shah,Niodita Gupta-Werner, Hui Lu, Malavika Venkatraman, Jennifer Whitty,Vipin Khare, Olivia Costa,Shuchita Kaila,Brea C. Lipe

HemaSphereno. S3 (2023)

引用0浏览0引用

Pb2110: predictors of frontline (fl) doublet or triplet regimen use among transplant-ineligible (tie) patients (pts) with newly diagnosed multiple myeloma (ndmm) using a machine learning approach

Matthew J. Pianko,Niodita Gupta-Werner,Bruno Émond,Patrick Lefèbvre,Marie-Hélène Lafeuille,Annelore Cortoos,Shuchita Kaila

HemaSphereno. S3 (2023): e496346b-e496346b

引用0浏览0引用

Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (drd) Versus Bortezomib, Lenalidomide, and Dexamethasone (vrd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Lucio N. Gordan,Rohan Medhekar,Alex Z. Fu,Abril Oliva Ramirez, N. Bonar, Bao‐Ngoc Nguyen, Michaela Spence, Rebecca K. McTavish, Timothy Disher,Shuchita Kaila, A. Patel

Bloodno. Supplement 1 (2023): 1963-1963

引用0浏览0引用

Trends in First Line Therapy (1L) Treatment Patterns including a Racial Sub-Analysis for Newly Diagnosed Multiple Myeloma (NDMM) in a Large US Community Oncology Network

Robert M. Rifkin, Yan Zhang,Jennifer S. Harper,Alex Z. Fu,Shuchita Kaila,Ira Zackon

AMERICAN JOURNAL OF HEMATOLOGY (2023): S30-S30

引用0浏览0引用

Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients, Including High-Risk Cytogenetic and African-American Subgroups, Treated with Daratumumab-based Frontline Regimens in Real-world

Voorhees Peter,Gordan N. Lucio,Medhekar Rohan,Chinaeke Eric,Fu Z. Alex,Cortoos Annelore,Kaila Shuchita,Rossi Adriana,Ailawadhi Sikander

AMERICAN JOURNAL OF HEMATOLOGY (2023): S21-S21

引用0浏览0引用

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States

Rafael Fonseca, Eric E Chinaeke,Niodita Gupta-Werner,Alex Z Fu,Shuchita Kaila

Mayo Clinic proceedings. Innovations, quality & outcomesno. 5 (2023): 430-436

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn